Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Unveiling Glycoproteins with Tung-Shing Mamie Lih, Ph.D.

  • Posted:

The following is the fifth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of glycoproteomics research with Tung-Shing Mamie Lih, PhD, an associate researcher at Johns Hopkins University School of Medicine. Transcript is edited for clarity.

Q: Please describe your academic/professional journey to date.

CPTAC Investigator Interview Series – Q & A with Tung-Shing Mamie Lih, Ph.D.

ML: During my graduate study my main research project was to develop software for N-linked glycoprotein identification from mass spectrometry-based glycoproteomic data and I found myself really enjoying what I was doing. It was a fulfilling experience—I felt I was contributing to the development of a valuable tool. Then I started my postdoctoral position at Dr. Hui Zhang’s lab at Johns Hopkins University, where I continued to work on developing analysis platforms and software while also utilizing bioinformatics/biostatistics to study proteins and protein modifications in various cancer types. Lately I have started doing some benchwork, too. It's really satisfying to analyze the data I generated myself. I also believe that this hands-on experience with wet lab experiments will be helpful for developing software and analysis methods.

Q: Please describe your current work at Johns Hopkins. What do you find most compelling about this work?

ML: Currently I'm working as a research associate at Johns Hopkins University (JHU) and my research is still focusing on studying proteins and protein modifications. Recently I have led a complete study on the detection of pancreatic ductal adenocarcinoma (PDAC)-associated glycoproteins in serum which was published in Molecular Cellular Proteomics early this year. So, in this study we utilized both quantitative glycoproteomic and global proteomic approaches to detect glyco-features in serum with matched PDAC tissues from our previous flagship paper. I find this work compelling, primarily due to its potential clinical significance. The glyco-features that could be detected in both tissue and serum, suggesting a promising avenue for utilizing blood tests in the detection of PDAC. [At present] I'm also involved in the CPTAC gastric cancer project, for which I performed the randomization of samples for TMT labeling.

Q: Could you briefly describe your achievements in the clear cell renal cell carcinoma (ccRCC) research project?

ML: I joined Hui’s group in 2018, and since then I’ve been involved in three CPTAC ccRCC studies (2019, 20222023). [The most recent of these] was a major accomplishment for me because in this study I analyzed the glycoproteomic data of the tissue cohort from the CPTAC ccRCC flagship paper. I think this study really demonstrates that glycoproteomics can expand our understanding of ccRCC by revealing previously uncaptured altered biological events. I also initiated an investigation of the interactions between N-linked glycosylation and phosphorylation [patterns] in ccRCC, which, to the best of my knowledge, had not been studied before.

Q: Could you describe the value of participating in collaborative groups like CPTAC?

ML: I think it's really nice to have these collaborations with researchers from different organizations. I think it [serves to] enhance the overall quality of the work. Engaging with professionals from different backgrounds is really significant in the whole research process and stimulates my creativity as well as my problem-solving skills. It's helped me produce research outcomes that are more impactful and more relevant because [in that environment] I am not expected to know everything; I can contribute my expertise and others can contribute theirs.

Q: What are some missing links you’ve identified in your field? How might these be overcome?

ML: I've done so many glycoproteomic analyses, and I think this type of data really does represent an important resource for understanding cancers. It allows people to investigate glycoproteins located on the cell surface and/or secreted from cells. However, causal effects represent [a gap in our understanding]–[the result] of molecular alterations cannot really be determined based on the data that we have right now. I think that establishing these causal relationships would help researchers to understand the [downstream] consequences of specific actions or conditions.

Q: For aspiring individuals, what career advice would you offer, considering your own journey and experiences?

ML: So, most of my work is computational. I think for anyone, if they're really interested in doing this kind of work, I would recommend learning a programming language-- you just need to learn one [to start]. It would also be good to build a fundamental knowledge of statistics. Even when doing wet lab experiments it is good to have a background in statistics.

Ultimately, there is one quote that inspires me every day: “Every job is a self-portrait of the person who did it. Autograph your work with excellence”. I hope others might find that quote inspiring, too.

Email